secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001564590-22-028750
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Pharma Q2 net loss $31.2M; XEN1101 Phase 3 on track for H2 2022
---------------------------------------------------------------------

- Net loss of $31.2M for Q2 2022, up from $22.1M in Q2 2021.
- Cash and securities $788.2M as of June 30, 2022, extended runway into 2026.
- Revenue fell to $0.5M from $2.2M, mainly due to wind-down of Neurocrine collaboration.
- XEN1101 Phase 3 X-TOLE2 expected to start in H2 2022 after positive FDA End-of-Phase 2 meeting.
- XEN496 EPIK study for KCNQ2-DEE anticipated to complete in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022028750/0001564590-22-028750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022028750/xene-8k_20220809.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer